Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.63 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14463409 | 1.00 | TAAR1 (0.63) | TAAR1SIGMAR1SLC18A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL17887872 | 1.00 | TAAR1 (0.63) | TAAR1SIGMAR1SLC18A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL15907606 | 0.88 | SIGMAR1 (0.59) | TAAR1SIGMAR1SLC18A2KMT2AMEN1 | |
| SCHEMBL25309034 | 0.83 | BCHE (0.74) | SIGMAR1KMT2AMEN1 | |
| SCHEMBL13981594 | 0.83 | ALDH1A1 (0.56) | SIGMAR1SMN1; SMN2ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL10396064 | 0.81 | ALDH1A1 (0.54) | SIGMAR1SMN1; SMN2ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL13996935 | 0.81 | CYP1A2 (0.55) | SIGMAR1SMN1; SMN2ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL14442996 | 0.81 | CYP1A2 (0.55) | SIGMAR1SMN1; SMN2ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL21779818 | 0.81 | ALDH1A1 (0.49) | TAAR1SIGMAR1SLC18A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL14442995 | 0.81 | CYP1A2 (0.55) | SIGMAR1SMN1; SMN2ALDH1A1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105367568-A | Riociguat preparation method | ZHEJIANG JINGXIN PHARMACEUTICAL CO LTD | 2016-03-02 | — | — | CN | claimed |
| EP-0722449-A1 | BOROPEPTIDE INHIBITORS OF THROMBIN WHICH CONTAIN A SUBSTITUTED PYRROLIDINE RING | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-24 | — | — | EP | claimed |
| EP-3580220-B1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
| CN-105367568-A | Riociguat preparation method | ZHEJIANG JINGXIN PHARMACEUTICAL CO LTD | 2016-03-02 | — | — | CN | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2431362-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2010131669-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2010-11-18 | — | — | WO | disclosed |
| US-20100204160-A1 | SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| US-7713961-B2 | Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090325940-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-7459460-B2 | Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-20070287087-A1 | Colored photosensitive resin composition, color filter, image sensor, and camera system | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-12-13 | — | — | US | disclosed |
| US-20070287087-A1 | Colored photosensitive resin composition, color filter, image sensor, and camera system | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-12-13 | — | — | US | disclosed |
| US-6472228-B2 | SYNTHETIC TRACER FOR USE IN DRUG SCREENING | LIFEPOINT, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020090661-A1 | Composition and methods for synthesis of novel tracers for detecting amphetamine and methamphetamine in samples | GENERAL CONFERENCE CORPORATION OF SEVENTH-DAY ADVENTISTS | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204160-A1 | SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF | PSEN1, PSEN2, BACE1 | TAAR1 277/4885SIGMAR1 1872/4885SLC18A2 133/4885 |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | TAAR1 1125/4885SIGMAR1 1105/4885SLC18A2 732/4885 |
| US-20090325940-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | PSEN1, PSEN2, BACE1 | TAAR1 277/4885SIGMAR1 1872/4885SLC18A2 133/4885 |
| US-20020090661-A1 | Composition and methods for synthesis of novel tracers for detecting amphetamine and methamphetamine in samples | NEFM, OPRM1, TAAR5 | TAAR1 25/4885SIGMAR1 76/4885SLC18A2 87/4885 |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | TAAR1 1793/4885SIGMAR1 2051/4885SLC18A2 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.